TuHURA Biosciences (HURA) reported second-quarter 2026 financial results, including cash and cash equivalents of $1.0 million as of June 30, 2026. The company said its April $50 million credit facility and royalty transaction extended its anticipated cash runway into 2028.
The Phase 3 immuno-oncology company also reported an IND filing for TBS-2025, its VISTA-inhibiting antibody, and outlined anticipated second-half 2026 milestones across its IFx-2.0, TBS-2025 and MDSC inhibitor programs.
- Research and development expenses were $6.6 million for the three months ended June 30, 2026, compared with $4.9 million a year earlier.
- General and administrative expenses were $2.1 million, compared with $1.9 million in the prior-year quarter.
- Net cash outflows from operating activities were $13.0 million for the six months ended June 30, 2026.
- Net cash flows from financing activities were $10.6 million for the first six months of 2026.
- TuHURA had approximately 63.7 million common shares outstanding as of June 30, 2026.
- The company expects to initiate a Phase 1b/2 trial of TBS-2025 in mutNPM1 relapsed/refractory AML during the second half of 2026.
$HURA Hedge Fund Activity
We have seen 42 institutional investors add shares of $HURA stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,760,168 shares (-71.8%) from their portfolio in Q2 2026, for an estimated $4,118,793
- NORTHERN TRUST CORP added 1,322,855 shares (+443.6%) to their portfolio in Q2 2026, for an estimated $3,095,480
- AQR CAPITAL MANAGEMENT LLC added 590,670 shares (+3580.3%) to their portfolio in Q1 2026, for an estimated $1,057,299
- GEODE CAPITAL MANAGEMENT, LLC removed 502,703 shares (-50.9%) from their portfolio in Q2 2026, for an estimated $1,176,325
- STATE STREET CORP removed 324,509 shares (-63.3%) from their portfolio in Q2 2026, for an estimated $759,351
- MORGAN STANLEY added 119,424 shares (+501.1%) to their portfolio in Q2 2026, for an estimated $279,452
- BANK OF NEW YORK MELLON CORP removed 89,906 shares (-42.5%) from their portfolio in Q2 2026, for an estimated $210,380
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
